For example, the fraction of p16 positive cases ranged from 43% to 100% in squamous cell carcinoma of the cervix [6,7], 9% to 98% in colorectal adenocarcinoma [8–10], 12% to 64% in hepatocellular carcinoma [11,12], 4% to 96% in malignant melanoma [13–15], 20% to 62% in mesothelioma [16–18], and 0% to 100% in liopsarcomas [19–21]. This evidence concerns the gene CDKN2A and colorectal adenocarcinoma.